Abstract: To provide a pretreatment liquid for inkjet textile printing, having excellent color development in the inkjet textile printing process, excellent color fastness to washing on printed fabrics, and little pretreatment trace residue. The solution therefor is a pretreatment liquid for inkjet textile printing containing 100 parts by mass of a cationic polymer (A), 5 parts by mass or more and less than 100 parts by mass of a (meth)acrylate-based vinyl copolymer (B), and 2 parts by mass or more and less than 30 parts by mass of a crosslinking agent (C), each being in solid content, and water, the liquid having a solid content by weight of 2 mass % or more and 30 mass % or less.

Abstract: A pretreatment composition is used to form a wet precoat layer for forming an image on a fabric by an inkjet method, wherein [1] the water-based ink composition contains water, a pigment, a resin emulsion, a water-soluble organic solvent, and a surfactant, [2] the pretreatment composition is used to form the wet precoat layer in which an amount of the pretreatment composition applied per unit area is more than 0.035 g/cm2 and less than 0.070 g/cm2, [3] the pretreatment composition contains water, more than 1.4 mass % and less than 10.5 mass % of a cationic polymer, and 0.1 mass % or more and less than 2.7 mass % of a crosslinking agent with respect to the total mass of the pretreatment composition, and [4] the cationic polymer contains at least one selected from an allylamine structural unit, a diallylamine structural unit, a diallylammonium structural unit, and an epihalohydrin structural unit.

Abstract: A tractor includes a working motor, a work machine including a roller configured to rotate by an output from the working motor, a support mechanism configured to support the work machine such that a working posture and a retracting posture are achievable, and a control device. The control device executes: an adherence amount acquisition process of acquiring an estimated adherence amount as an estimated value for the amount of mud attached to the roller; and a mud removal process of, when the estimated adherence amount is equal to or more than a determination adherence amount, removing the mud from the roller by driving the working motor in a state where the work machine takes the retracting posture.

Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.

Abstract: An embodiment of the present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate thereof.

Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.

Abstract: The present invention is to provide a medicament for treating and/or preventing tauopathy by activating the voltage-gated sodium channel (Nav). The present invention relates to a medicament for treating and/or preventing tauopathy, comprising a Nav activator as an active ingredient.

Abstract: An inflammatory marker is calculated using a nonlinear function including, as variables, a parameter associated with an erythrocyte aggregation and another parameter associated with an erythrocyte density. The parameter associated with the erythrocyte aggregation is calculated based on a syllectogram measured from a blood specimen. The parameter associated with the erythrocyte density is measured from the blood specimen.

Abstract: A prophylactic or therapeutic agent for tauopathy, containing an inhibitor of ?2? of the voltage-dependent calcium channel is provided by the present invention.

Abstract: The present invention provides an ?-synuclein aggregate binding agent that has high binding selectivity for an ?-synuclein aggregate. The ?-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: in the formula (I), R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii): R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.

Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.

Abstract: An image reading device reads two types of documents, a first document having a first size and a second document having a second size larger than the first size. A controller of the device causes the first document reader to read the first document and generate image data when the operation unit accepts a command. The first document reader reads a portion of the second document and generates image data on tilt of the second document when the operation unit accepts a command. The document tilt detector detects tilt of the second document based on the image data for detecting tilt of the second document. The document transporter stops transport of the second document when the document tilt detector detects tilt of the second document. The second document reader reads the second document and generates image data when the document tilt detector detects no tilt of the second document.

Abstract: The purpose of the present invention is to provide a technique for imaging the brain of a live animal and application of the technique. A radiolabeled dibenzoazepine derivative, which shows excellent brain parmeability, high receptor selectivity and high quantitativity, is used for imaging a live animal body. A dibenzoazepine derivative is used for treating a disease in which hM4D receptor or hM3D receptor participates. Further, a radiolabeled dibenzoazepine derivative is used for imaging an axonal end which is innervated by a nerve cell.

Abstract: An image reading device reads two types of documents, a first document having a first size and a second document having a second size larger than the first size. A controller of the device causes the first document reader to read the first document and generate image data when the operation unit accepts a command. The first document reader reads a portion of the second document and generates image data on tilt of the second document when the operation unit accepts a command. The document tilt detector detects tilt of the second document based on the image data for detecting tilt of the second document. The document transporter stops transport of the second document when the document tilt detector detects tilt of the second document. The second document reader reads the second document and generates image data when the document tilt detector detects no tilt of the second document.

Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and [Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.

Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.

Abstract: A data communication device that performs e-mail communication includes: an e-mail transmitter that attaches an image to an e-mail, and then transmits the e-mail; an image data detector that detects a data amount of an input image; an image data amount determiner that determines whether or not a data amount of the image attached to the e-mail exceeds a preset data amount; a communication controller that enables transmission of the e-mail if the data amount of the image does not exceed the preset data amount; and a data amount controller that performs data amount reduction processing of reducing the image data amount if the data amount of the image exceeds the preset data amount.

Abstract: An inflammatory marker is calculated using a nonlinear function including, as variables, a parameter associated with an erythrocyte aggregation and another parameter associated with an erythrocyte density. The parameter associated with the erythrocyte aggregation is calculated based on a syllectogram measured from a blood specimen. The parameter associated with the erythrocyte density is measured from the blood specimen.

Abstract: A temperature adjuster (20) is configured to adjust temperature associated with a first gas supplying medium (10) for providing first gas to be mixed. A first flow rate controller (30) is configured to control a flow rate of the first gas. A second flow rate controller (40) is configured to control a flow rate of second gas to be mixed that is different from the first gas. A mixer (50) is configured to supply mixed gas in which the first gas supplied by the first flow rate controller (30) and the second gas supplied by the second flow rate controller (40) have been mixed.

Abstract: The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.